NCT05954546View on ClinicalTrials.gov

A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

CompletedOBSERVATIONAL
Enrollment

275

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Metastatic Melanoma
Interventions
DRUG

Enco+bini

Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment

Trial Locations (1)

10017

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05954546 - A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings | Biotech Hunter | Biotech Hunter